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Abstract 
Objective: The purpose of this systematic review with meta-analysis is to determine the diagnostic 
accuracy of the ID Migraine as a decision rule for identifying patients with migraine.  
 
Background: The ID Migraine screening tool is designed to identify patients with migraine in 
primary care settings. Several studies have validated the ID Migraine across various clinical settings, 
including primary care, neurology departments, headache clinics, dental clinics, ENT and 
ophthalmology. 
 
Method: A systematic literature search was conducted to identify all studies validating the ID 
Migraine, with the International Headache Criteria as the reference standard. The methodological 
quality of selected studies was assessed using the Quality of Diagnostic Accuracy Studies tool. All 
selected studies were combined using a bivariate random effects model. A sensitivity analysis was 
also conducted, pooling only those studies using representative patient groups (primary care; 
neurology departments; and headache clinics) to determine the potential influence of spectrum bias 
on the results. 
 
Results: Thirteen studies incorporating 5,866 patients are included. The weighted prior probability 
of migraine across the thirteen studies is 59%. The ID Migraine is shown to be useful for ruling out 
rather than ruling in migraine, with a greater pooled sensitivity estimate (0.84, 95% CI 0.75 – 0.90) 
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than specificity (0.76, 95% CI 0.69 – 0.83). A negative ID Migraine score reduces the probability of 
migraine from 59% to 23%. The sensitivity analysis reveals similar results. 
  
Conclusions: This systematic review quantifes the diagnostic accuracy of the ID Migraine as a brief, 
practical and easy to use diagnostic tool for Migraine. Application of the ID Migraine as a diagnostic 
tool is likely to improve appropriate diagnosis and management of Migraine sufferers. 
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Background 
Migraine is a common disorder affecting approximately 18% of women and 6-8% of men. 1-2 
Despite the prevalance and burden of migraine,3-5 less than half of current migraineurs have ever 
received a medical diagnosis of migraine,2 with only one-third receiving migraine-specific 
prescription medications. 6-7 Recognizing and diagnozing migraine is challenging for a number of 
reasons, including low rates of medical consultation specifically for headache. Less than half of 
migraineurs, even those with highly disabling headaches, consult a doctor for a complaint of 
headache. 2 Increasing patient consultation for headache and improving the accuracy of clinical 
diagnosis is important to improve the quality of life for many individuals who are not diagnozed or 
treated appropriately for migraine. 8 
 
Taking a thorough case history is the single most important factor when assessing patients with 
headache, allowing for the identification of a headache diagnosis and determining the treatment 
plan. The International Headache Society (IHS) developed a comprehensive headache classification 
system in 1988 which includes diagnostic categories of migraine with and without aura9; this system 
was updated in 2004.10 However, this classification system has been criticised for being too 
cumbersome for primary care or generalist physicians to apply.11 Therefore efforts have been made 
to develop a more efficient method of diagnozing migraine than the full IHS criteria. A previous 
review demonstrated the diagnostic utility of various individual symptoms (including nausea, 
photophobia, phonophobia, exacerbation by physical activity, and aura) in the diagnosis of migraine 
using the IHS criteria as the reference standard for diagnosis. 12 However, as migraine is a symptom 
complex, it is unlikely that any one symptom identified in the clinical examination will be sufficient 
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to rule in or out the condition. US researchers addressed this limitation developing the three item 
Identification of Migraine (ID Migraine), a brief, self-administered clinical prediction rule for adults, 
which they then validated prospectively. 13 The three items relate to presence of photophobia, 
nausea and disability (inability to work, study or do what you needed to do for at least one day). A 
patient scores positive for migraine if they endorse two of the three items on the ID Migraine. 
However, as this tool was derived as a screening tool to identify migraine in primary care settings, 
two pre-screening items are included to identify eligible patients for the ID Migraine test. Firstly, 
patients must report two or more headaches in the previous three months. Secondly, patients must 
indicate that they wish to speak to a healthcare professional about their headaches or that they have 
experienced a headache that had limited their ability to work, study or enjoy life. 13 Several studies 
have validated the ID Migraine screening tool since it’s derivation in 2003. The aim of this study is 
to perform a comprehensive systematic review and meta-analysis of validation studies of the ID 
Migraine to determine its accuracy as a decision rule for identifying patients with migraine. 
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Methods 
Search strategy 
The PRISMA guidelines for the reporting of systematic reviews and meta-analyses were followed to 
conduct this review.14 We aimed to identify all studies validating the ID Migraine irrespective of 
setting. A systematic literature search was conducted in November 2010 and included the following 
search engines: the Cochrane Library, EMBASE and PubMed. A combination of the following 
keywords and MeSH terms were used: ‘migraine disorders’, ‘ID Migraine’, ‘sensitivity and 
specificity’, ‘diagnose/diagnosis/diagnostic/diagnosis, differential’ This search was supplemented by 
handsearching references of retrieved articles and searching Google Scholar. No restrictions were 
placed on language. 
 
Study selection and data extraction 
Studies were included if they met the following inclusion criteria: 1) validate the ID Migraine using 
the IHS criteria as the reference standard 9-10; 2) use a cohort or cross-sectional study design; 3) 
include sufficient data to allow for the calculation of sensitivity, specificity, negative and postive 
predictive values and the prevalence of migraine. Studies that included patients with a chronic 
disease, were excluded from the analysis. Data was extracted on study setting, pre-screening items 
used, patient characteristics and prevalence of migraine. The number of true positives, false 
positives, true negatives and false negatives for the ID Migraine were also extracted from each 
validation study and a 2 x 2 table was constructed. Authors were contacted to provide further 
information when there was insufficient detail in an article to construct the 2 x 2 table.  
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Quality assessment 
The methodological quality of the selected studies was evaluated independently by two reviewers 
(GC & SH) using the Quality of Diagnostic Accuracy Studies (QUADAS) tool, a validated tool for 
the quality assessment of diagnostic accuracy studies.15-16 This tool was modified to ensure 
appropriateness for the present study and included 13 of the 14 questions from the QUADAS tool. 
If no consensus was achieved studies were evaluated by a third independent reviewer (TF). 
 
Data synthesis and analysis 
A bivariate random effects model was used to estimate summary estimates of sensitivity and 
specificity and their corresponding 95% confidence interval. Positive and negative likelihood ratios 
were also reported. This approach was used as it preserves the two-dimensional nature of the 
original data and takes into account both study size and heterogeneity beyond chance between 
studies. 17 Using Bayes theorem the post-test odds of migraine were also estimated by multiplying 
the pretest odds by the likelihood ratio, where pre-test odds are calculated by dividing the pre-test 
probability by (1-pre-test probability) and the post-test probability equals post-test odds divided by 
(1 + post-test odds).18 
 
We also plotted the individual and summary estimates of sensitivity and specificity for the ID 
Migraine in a summary receiver operating characteristic (ROC) graph, plotting the mean sensitivity 
(true positive) on the y-axis against 1- specificity (false negative) on the x axis. We also plotted the 
95% confidence region and 95% prediction region around the pooled estimates to illustrate the 
Page 10 of 31Headache
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
9 
 
precision with which the pooled values were estimated (confidence ellipse around the mean value) 
and to illustrate the amount of between study variation (prediction ellipse). We assessed 
heterogeneity visually using the summary ROC plots and statistically by using the variance of logit 
transformed sensitivity and specificity, with smaller values indicating less heterogeneity among 
studies. 
We used Stata version 10.1 (StataCorp College Station, Tx, USA), particularly the metandi 
commands for all statistical analyses. 
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Results 
Study Identification 
A flow diagram of the search strategy is presented in Figure 1. Two researchers (SH, GC) screened 
all potential articles. The search strategy yielded 4,111 papers of which 4,091 were excluded based on 
their title or abstract. Eleven of the remaining 20 articles met the inclusion criteria and were selected 
for analysis.13, 19-28. However, one article contained information on three different study groups, thus 
resulting in thirteen studies for inclusion.  
 
INSERT FIGURE 1 HERE 
 
Study characteristics 
Table 1 summarizes the characteristics of the included studies. One study was based in the US 13, 
three in Italy 19, 23-24, one in Portugal 20, four in Turkey 21, 25-26, 28, one in Korea 22 and one in Singapore 
27. The mean weighted prior probability is 59.1%. The included studies range in size from 37 24 to 
1,816 21 participants. A total of 5,866 participants are included in the analysis.  
 
INSERT TABLE 1 HERE 
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Study Quality 
The summary diagram of the quality assessment is shown in Figure 2. The overall quality of the 
included studies is moderate to good. However, it is unclear whether test review bias was avoided in  
twelve of the thirteen studies as it was not explicity stated that the results from the ID Migraine were 
interpreted without the knoweledge of the reference standard (IHS criteria). It was also unclear 
whether the IHS criteria was interpreted blind to the results of the ID Migraine in five studies. 
Furthermore, ten studies did not clearly report the time difference between assessing patients using 
the ID migraine and the IHS criteria. Finally, spectrum bias is also identified as a potential source of 
bias in seven studies as they include patients who are not representative of patients who will receive 
the ID Migraine in primary care, neurology departments or headache clinics. In order to determine 
the potential influence of spectrum bias on the meta-analysis, a sensitivity analysis was conducted, 
pooling only those studies using representative patient groups (primary care; neurology departments; 
and headache clinics i.e. similar to the setting of intended use of ID Migraine).13, 19-21, 27-28 
 
INSERT FIGURE 2 HERE 
 
Diagnostic test accuracy of all included studies 
The pooled sensitivity, specificity and the respective variance of the logit-transformed sensitivity and 
specificity for the thirteen studies are presented in Table 2. The positive and negative likelihood 
ratios are also presented in Table 2. These results indicate the diagnostic utility of the ID migraine in 
ruling out rather than ruling in migraine, with a greater sensitivity (0.84, 95% CI 0.75-0.90) than 
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specificity (0.76, 95% CI 0.69-0.83). Using Bayes thereom a positive score on the ID Migraine 
increases the pre-test probability from 59% to 84%, whereas a negative ID Migraine score reduces 
the probability of migraine to 23%. 
 
INSERT TABLE 2 HERE 
The individual and summary estimates of sensitivity and specificity, the 95% confidence region and 
95% prediction region are presented in a ROC graph in figure 3. The 95% confidence region is 
narrow thus indicating precision of the pooled estimate. The prediction region (amount of variation 
between studies) is wider thus suggesting heterogeneity across studies. The heterogeneity is greater 
in relation to sensitivity estimates compared to specificity, with a smaller variance of the logit-
transformed specificity (Table 2). 
INSERT FIGURE 3 HERE 
 
Sensitivity analysis 
The pooled sensitivity, specificity and the respective variance of the logit-transformed sensitivity and 
specificity for the sensitivity analysis, which pools data from 6 studies are presented in Table 2. The 
positive and negative likelihood ratios are also displayed. The mean weighted prior probability of 
migraine for the 6 included studies is 60%. As with the previous analysis, the ID Migraine is found 
to be greater at ruling out migraine, with a sensitivity of 0.88 (95% CI 0.75-0.93). Similar to the 
previous analysis a positive score on the ID Migraine increases the pre-test probability from 60% to 
82%, whereas a negative ID Migraine score reduces the probability of migraine to 21%. The 
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variation between studies is greater for sensitivity as in the previous analysis pooling all thirteen 
studies. The variance of the logit-transformed specificity is also smaller than that of the previous 
analysis pooling all thirteen studies. (Table 2). The summary ROC graph is displayed in figure 4. 
 
INSERT FIGURE 4 HERE 
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Discussion 
Principal findings 
This systematic review shows that the ID Migraine is a useful tool, particularly for ruling out 
migraine, in symptomatic patients with headache when assessed against the IHS criteria. A negative 
ID Migraine score, less than two positive responses, reduces the post-test probability of  migraine 
from 59% to 23%. These results relate to various clinical settings including primary care, neurology, 
dental clinics, ENT, ophthalmology, workplace and school. The sensitivity analysis which removed 
those studies with potential to introduce spectrum bias, revealed similar results, supporting the use 
of  the ID Migraine to rule out migraine in symptomatic patients presenting to primary care, 
neurology departments or headache clinics. 
 
Context of previous studies 
Previous reviews have sought to identify a more efficient method of diagnozing migraine than the 
full IHS criteria. One meta-analysis identified nausea, photophobia, phonophobia, and exacerbation 
of headache with physical activity as the best individual symptoms for ruling in or out migraine.11 A 
more recent review examined the diagnostic utility of combinations of clinical features in identifying 
patients with migraine.12 In this review only four studies examining combinations of clinical features 
were identified. In addition, each of the studies represented a different clinical prediction rule thus 
preventing any pooled analysis. Though ID Migraine was identified in this review, only the 
derivation study was reported. The present study’s focus on the ID migraine allows us to determine 
the diagnostic accuracy of the ID migraine across a number of clinical settings and countries. 
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Strengths and limitations of this study 
Following a systematic search we identified 13 studies validating the ID Migraine. This is the first 
study to pool the various validation studies to determine the accuracy of the ID Migraine across 
various clinical settings and countries.We conducted a sensitivity analysis to determine whether there 
are any differences when restricting pooled analysis to settings similar to the intended use of the ID 
Migraine (primary care; headache clinics; and neurology departments). Our findings show little 
difference in the pooled estimates when restricting analysis to these three settings, thus supporting 
the generalizability of the overall study findings. 
 
The results of this meta-analysis should be inte preted in the context of the study limitations. Firstly, 
although migraine is more prevalent in women we do not know whether the diagnostic accuracy of 
the ID Migraine varies as a function of gender. Unfortunately, the data were not available for men 
and women separately. Secondly, methodological quality of  the studies needs to be considered. For 
example, ten studies did not clearly report the time between assessing patients using the ID Migraine 
and the neurologists assessment using the IHS criteria. Finally, the pretest probability of  patients 
presenting to primary care or headache clinics with headache as the primary complaint is likely to be 
lower than the mean weighted prior probability used in this analysis (60%). Ebell estimates a 
prevalence of  33% to be a reasonable estimate for patients attending primary care with a 
headache.29  This is similar to the prevalence estimate of  38.2% reported in a study involving 
patients attending their GP with a primary complaint of  headache.27 
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 The higher prevalence in several of the included studies is an artefact of study design as eight of  the 
thirteen studies used additional pre-screening items (other than experienced a headache in the past 
three months), as recommended by Lipton. The most problematic pre-screening item recommended 
by Lipton is  ‘experience headache limiting your ability to work, study or enjoy life’, as this exact 
item is also one of the three items on the ID Migraine. Therefore if a patient responds positively to 
this item at the pre-screening stage, that patient will automatically have a score of one on the ID 
Migraine before even taking the test. While pre-screening items are important it is not considered 
appropriate to use the same item at both the pre-screening and the screening phase. Furthermore, 
we question the appropriateness of the term pre-screening and screening in relation to the ID 
Migraine. It may be more useful to consider the ID Migraine as a two step rule, with the pre-
screening items representing the screening phase and the three item ID Migraine representing the 
diagnostic phase that would then determine subsequent management (treatment and/or 
prophylaxis).  
 
Implications for practice 
The results of this study confirm the diagnostic utility of the ID Migraine as a brief, easy to use 
diagnostic tool. Following a positive score on the ID Migraine, a physican could consider starting 
their patient on migraine specific medication and monitor their response to treatment so ensuring 
that that symptoms improve or in the case of prophylaxis, migraine headache frequency is reduced. 
If a patient does not respond to treatment or prophylaxis it is possible that their result on the ID 
Migraine was a false positive and the patient will require further diagnostic assessment. On the other 
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hand if a patient has a negative result on the ID Migraine, a physican can have greater certaintly that 
the patient does not have a migraine, and can pursue alternative diagnoses.  
Conclusions 
Migraine is underdiagnosed and undertreated 6, in clinical care. This systematic review quantifes the 
diagnostic accuracy of the ID Migraine as a brief, practical and easy to use diagnostic tool for 
Migraine. Application of the ID Migraine as a diagnostic tool is likely to improve appropriate 
diagnosis and management of Migraine sufferers. 
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Table 1: Characteristics of studies included in the review 
Authors 
(country) 
Study setting Pre-screening items used Participants: n, sex, mean 
age (range) 
Prevalence 
of migraine † 
Lipton et al 2003  
(US) 
Primary care  1) 2+ headaches in previous 3 months 
2) Experienced headache limiting their ability to 
work, study, enjoy life 
OR 
Wish to speak to healthcare professional 
about their headaches 
n=443 
110men; 333 women 
39.3 years (18-55) 
 
79% 
Brighina et al 
2007 
(Italy) 
Headache 
centre* 
1) 2+ headaches in previous 3 months 
2) Experienced headache limiting their ability to 
work, study, enjoy life 
n=222 
59 men; 163 women 
38.7 years (18-65) 
67% 
Gil-Gouveia et al 
2010 
(Portugal) 
Headache 
outpatients 
1) 2+ headaches in previous 3 months 
 
n=131 
21 men; 110 women 
39.2 years (18-73) 
63.4% 
Karli et al 2007 
(Turkey) 
Neurology 
outpatients 
1) 2+ headaches in previous 3 months 
2) Experienced headache limiting their ability to 
work, study, enjoy life 
OR 
Wish to speak to healthcare professional 
about their headaches 
n=1816 
45.2 years  
 
50.5% 
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Kim et al 2006 
(Korea) 
TMJ and 
orofacial pain 
clinic 
1) 2+ headaches in previous 3 months 
2) Experienced headache limiting their ability to 
work, study, enjoy life 
OR 
Wish to speak to healthcare professional 
about their headaches 
n=176 
33 men; 143 women 
30.7 years (18-55) 
18.8% 
Di Piero e tal 
2007 
(Italy) 
Primary care Sensitisation campaign stressing impact of 
headache on quality of life. People asked to 
respond if: 
1) Suffered from headaches 
2) Wish to speak to healthcare professional 
about their headaches 
n=195 
16% men; 84% women 
40.5 years 
92% 
Di Paolo et al 
2009 
(Italy) 
Dental clinic No pre-screening questions applied N=37 
5 men;32 women 
34 years 
 
91.9% 
Siva et al 2008 
(Turkey) 
Workplace 1) 2+ headaches in previous 3 months 
2) Experienced headache limiting their ability to 
work, study, enjoy life 
OR 
Wish to speak to healthcare professional 
about their headaches 
n=227 
78 men; 149 women 
31.9 years (18-55) 
 
51.5% 
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Zarifoglu et al 
2007 
(Turkey) 
School setting 1) 2+ headaches in previous 3 months 
 
n=1014 
14.67 years (12-17) 
 
33% 
Khu et al 2008 
(Singapore) 
Primary care 1) Patients consulting Gp with primary 
complaint of headache 
 
n=584 
25% men; 75% women 
37 years (8-74) 
 
38.2% 
Ertas et al 2008 
(Turkey) 
Neurology 
outpatients 
1) 2+ headaches in previous 3 months 
2) Experienced headache limiting their ability to 
work, study, enjoy life 
OR 
Wish to speak to healthcare professional 
about their headaches 
n=530 
36.2 men; 63.8% women 
46.5 years  
63.8% 
Ertas et al 2008 
(Turkey) 
Ophthalmology 
outpatients 
1) 2+ headaches in previous 3 months 
2) Experienced headache limiting their ability to 
work, study, enjoy life 
OR 
Wish to speak to healthcare professional about 
their headaches 
n=228 
41.9% men;58.1% women 
47.3 years 
65.4% 
Ertas et al 2008 ENT 1) 2+ headaches in previous 3 months 
2) Experienced headache limiting their ability to 
N=263 54% 
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(Turkey) outpatients work, study, enjoy life 
OR 
Wish to speak to healthcare professional about 
their headaches 
47.1% men; 52.9% women 
43.3 years 
 
*headache centres not requiring the additional pre-screening item as patients are referred to headache centre therefore seeking healthcare 
advice 
† Mean weighted prior probability=59.1% 
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Table 2. Summary estimates of sensitivity, specificity and positive and negative likelihood ratio’s for all included studies and for sensitivity 
analysis 
 No. of 
studies 
(patients) 
Sensitivity 
(95% CI) 
Variance 
Logit 
Sensitivity 
Specificity 
95% CI 
Variance 
Logit 
Specificity 
+ LR 
(95% CI) 
-LR 
(95% CI) 
 
ID Migraine 
(All studies) 
 
13 (5,866) 
 
0.84(0.75-0.90) 
 
0.87 
 
0.76(0.69-0.83) 
 
0.39 
 
3.55(2.76-4.57) 
 
0.21(0.14-0.32) 
 
 
ID migraine 
(Sensitivity 
analysis) 
 
6 (3,142) 
 
0.88(0.75-0.93) 
 
0.87 
 
0.71(0.63-0.78) 
 
0.19 
 
2.99(2.45-3.60) 
 
0.17(0.11-0.33) 
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Figure 1. Search strategy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*One article contained data on 3 different settings  
Records identified through 
database searching  
(n=4293) 
Additional records identified through 
google scholar & citation searching 
(n=0) 
Records after duplicates removed  
(n=4111) 
Records excluded after reading title 
and abstract (n=4091) 
Full-text articles assess d for 
eligibility  
(n=20) 
Articles included analysis (n=11)* 
Studies included analysis (n=13) 
Excluded (n=9) 
Chronic disease patient group (n=1) 
Not appropriate reference test (n=3) 
Only a subset of people received reference test (n=2) 
Includes only those with confirmed diagnosis (n=1) 
Not validating ID Migraine (n=1) 
Report preliminary validation results which are incorporated 
in the full validation study  (n=1) 
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Figure 2. Quality assessment 
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Figure 3. Receiver Operating characteristic graph with 95% confidence region and 95% 
prediction region for all included studies (n=13) 
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Figure 4. Receiver Operating characteristic graph with 95% confidence region and 95% 
prediction region for sensitivity analysis (primary care; headache clinics; and neurology 
departments) (n=6) 
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